The platelet P2Y12 receptor for adenosine diphosphate: Congenital and drug-induced defects

Blood

Volumn 117, Issue 7, 2011, Pages 2102-2112

  Cattaneo, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADENYLATE CYCLASE; CANGRELOR; CLOPIDOGREL; CYCLIC AMP; DESMOPRESSIN; HEPARIN; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; THROMBOCYTE RECEPTOR; TICAGRELOR; TICLOPIDINE; ADENOSINE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; P2RY12 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BLEEDING TENDENCY; BRAIN ISCHEMIA; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONGENITAL PURINERGIC P2Y12 RECEPTOR DEFICIENCY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DYSPNEA; FRAMESHIFT MUTATION; HUMAN; LOADING DRUG DOSE; MONOTHERAPY; MORTALITY; POINT MUTATION; POSTOPERATIVE HEMORRHAGE; POSTTRAUMATIC COMPLICATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECONDARY STRUCTURE; REPEATED DRUG DOSE; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE DISORDER; THROMBOCYTE FUNCTION; THROMBOGENESIS; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG EFFECT; FEMALE; GENETICS; MALE; MOUSE; MUTATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; THROMBOCYTE;

ADENOSINE; ADENOSINE DIPHOSPHATE; ANIMALS; BLOOD PLATELET DISORDERS; BLOOD PLATELETS; FEMALE; HEMORRHAGE; HUMANS; MALE; MICE; MUTATION; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; SIGNAL TRANSDUCTION; THIOPHENES; TICLOPIDINE;

EID: 79951848755     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-263111     Document Type: Review

References (97)

1. Packham MA, Mustard JF. Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective. Semin Thromb Hemost. 2005;31(2):129-138. (Pubitemid 40605188)
2. Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol. 1999;19(10):2281-2285. (Pubitemid 29477827)
3. Cattaneo M, Canciani MT, Lecchi A, et al. Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. Blood. 1990;75(5):1081-1086. (Pubitemid 20086813)
4. Cattaneo M, Akkawat B, Kinlough-Rathbone RL, Packham MA, Cimminiello C, Mannucci PM. Ticlopidine facilitates the deaggregation of human platelets aggregated by thrombin. Thromb Haemost. 1994;71(1):91-94. (Pubitemid 24023792)
5. Trumel C, Payrastre B, Plantavid M, et al. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood. 1999;94(12):4156-4165.
6. Abbracchio MP, Burnstock G, Boeynaems JM, et al. The recently deorphanized GPR80 (GPR99) proposed to be the P2Y15 receptor is not a genuine P2Y receptor. Trends Pharmacol Sci. 2005;26(1):8-9. (Pubitemid 40052702)
7. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci U S A. 1998;95(14):8070-8074. (Pubitemid 28326067)
8. Cattaneo M. The platelet P2 receptors. In: Michelson AD, ed. Platelets. San Diego, CA: Academic Press; 2006:201-220.
9. Savi P, Zachayus JL, Delesque-Touchard N, et al. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A. 2006;103(29):11069-11074. (Pubitemid 44148419)
10. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84(5):891-896.
11. Ding Z, Kim S, Dorsam RT, Jin J, Kunapuli SP. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood. 2003;101(10):3908-3914.
12. Zhong X, Kriz R, Seehra J, Kumar R. N-linked glycosylation of platelet P2Y12 ADP receptor is essential for signal transduction but not for ligand binding or cell surface expression. FEBS Lett. 2004;562(1):111-117. (Pubitemid 38388456)
13. Kauffenstein G, Hechler B, Cazenave JP, Gachet C. Adenine triphosphate nucleotides are antagonists at the P2Y receptor. J Thromb Haemost. 2004;2(11):1980-1988. (Pubitemid 40192752)
14. Quinton TM, Kim S, Jin J, Kunapuli SP. Lipid rafts are required in Galpha(i) signaling downstream of the P2Y12 receptor during ADP-mediated platelet activation. J Thromb Haemost. 2005;3(5):1036-1041.
15. Haslam RJ. Interactions of the pharmacological receptors of blood platelets with adenylate cyclase. Ser Haematol. 1973;6(3):333-350.
16. Savi P, Pflieger AM, Herbert JM. cAMP is not an important messenger for ADP-induced platelet aggregation. Blood Coagul Fibrinolysis. 1996;7(2):249-252. (Pubitemid 26167952)
17. Gratacap MP, Herault JP, Viala C, et al. FcgammaRIIA requires a Gi-dependent pathway for an efficient stimulation of phosphoinositide 3-kinase, calcium mobilization, and platelet aggregation. Blood. 2000;96(10):3439-3446.
18. Dangelmaier C, Jin J, Smith JB, Kunapuli SP. Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway. Thromb Haemost. 2000;85(2):341-348. (Pubitemid 32140582)
19. Hirsch E, Bosco O, Tropel P, et al. Resistance to thromboembolism in PI3Kgamma-deficient mice. FASEB J. 2001;15(11):2019-2021.
20. Jackson SP, Yap CL, Anderson KE. Phosphoinositide 3-kinases and the regulation of platelet function. Biochem Soc Trans. 2004;32(2):387-392. (Pubitemid 38582133)
21. Garcia A, Kim S, Bhavaraju K, Schoenwaelder SM, Kunapuli SP. Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways. Biochem J. 2010;429(2):369-377.
22. Jarvis GE, Humphries RG, Robertson MJ, Leff P. ADP can induce aggregation of human platelets via both P2Y(1) and P(2T) receptors. Br J Pharmacol. 2000;129(2):275-282. (Pubitemid 30073900)
23. Kauffenstein G, Bergmeier W, Eckly A, et al. The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin: a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett. 2001;505(2):281-290.
24. Cattaneo M. The P2 receptors and congenital platelet function defects. Semin Thromb Hemost. 2005;31(2):168-173. (Pubitemid 40613080)
25. Cattaneo M, Lombardi R, Zighetti ML, et al. Deficiency of [33P]2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production: evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production. Thromb Haemost. 1997;77(5):986-990. (Pubitemid 27239127)
26. Cattaneo M, Lecchi A, Lombardi R, Gachet C, Zighetti ML. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet 'primary secretion defect' are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol. 2000;20(11):E101-E106.
27. Lecchi A, Cattaneo M, Mannucci PM. ADP potentiates platelet-dense granule secretion induced by U46619 or TRAP through its interaction with the P2cyc receptor [abstract]. Haematologica. 2000;85(suppl):83.
28. Li Z, Zhang G, Le Breton GC, Gao X, Malik AB, Du X. Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases. J Biol Chem. 2003;278(33):30725-30731. (Pubitemid 36994579)
29. Eckly A, Gendrault JL, Hechler B, Cazenave JP, Gachet C. Differential involvement of the P2Y1 and P2YT receptors in the morphological changes of platelet aggregation. Thromb Haemost. 2001;85(4):694-701. (Pubitemid 32293707)
30. Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci PM. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood. 1992;80(11):2787-2796.
31. Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest. 2001;107(12):1591-1598. (Pubitemid 32574645)
32. Cattaneo M, Zighetti ML, Lombardi R, et al. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci U S A. 2003;100(4):1978-1983. (Pubitemid 36254559)
33. Andre P, Delaney SM, LaRocca T, et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest. 2003;112(3):398-406. (Pubitemid 38063768)
34. Nurden P, Savi P, Heilmann E, et al. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets: its influence on glycoprotein IIb-IIIa complex function. J Clin Invest. 1995;95(4):1612-1622.
35. Cattaneo M, Lombardi R, Bettega D, Lecchi A, Mannucci PM. Shear-induced platelet aggregation is potentiated by desmopressin (DDAVP) and inhibited by ticlopidine. Arterioscler Thromb. 1993;13(3):393-397. (Pubitemid 23075628)
36. Cattaneo M, Zighetti ML, Lombardi R, Mannucci PM. Role of ADP in platelet aggregation at high shear: studies in a patient with congenital defect of platelet responses to ADP. Br J Haematol. 1994;88(4):826-829. (Pubitemid 24375799)
37. Resendiz JC, Feng S, Ji G, Francis KA, Berndt MC, Kroll MH. Purinergic P2Y12 receptor blockade inhibits shear-induced platelet phosphatidylinositol 3-kinase activation. Mol Pharmacol. 2003;63(3):639-645. (Pubitemid 36297335)
38. Cattaneo M, Lecchi A. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost. 2007;5(3):577-582. (Pubitemid 46680692)
39. Gachet C, Cattaneo M, Ohlmann P, et al. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol. 1995;91(2):434-444.
40. Shiraga M, Miyata S, Kato H, et al. Impaired platelet function in a patients with P2Y12 deficiency caused by a mutation in the translation initiation codon. J Thromb Haemost. 2005;3(10):2315-2323. (Pubitemid 41727212)
41. Dawood BB, Daly M, Makris M, Mumford A, Watson S, Wilde J. Identification of a novel homozygous P2Y12 mutation in a patient with a mild platelet-based bleeding disorder [abstract]. J Thromb Haemost. 2009;7(suppl 2):Abstract PPMO-076.
42. Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost. 2003;1(7):1628-1636.
43. Conley PB, Jurek MM, Vincent D, Lecchi A, Cattaneo M. Unique mutations in the P2Y12 locus of patients with previously described defects in ADP-dependent aggregation [abstract]. Blood. 2001;98:43.
44. Fontana G, Ware J, Cattaneo M. Haploin-sufficiency of the platelet P2Y12 gene in a family with congenital bleeding diathesis. Haematologica. 2009;94(4):581-584.
45. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409(6817):202-207. (Pubitemid 32144286)
46. Moro S, Hoffmann C, Jacobson KA. Role of the extracellular loops of G protein-coupled receptors in ligand recognition: a molecular modeling study of the human P2Y1 receptor. Biochemistry. 1999;38(12):3498-3507.
47. Moro S, Guo D, Camaioni E, Boyer JL, Harden TK, Jacobson KA. Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J Med Chem. 1998;41(9):1456-1466. (Pubitemid 28198975)
48. Remijn JA, IJsseldijk MJ, Strunk AL, et al. Novel molecular defect in the platelet ADP receptor P2Y12 of a patient with haemorrhagic diathesis. Clin Chem Lab Med. 2007;45(2):187-189. (Pubitemid 46294687)
49. Daly ME, Dawood BB, Lester WA, et al. Identification and characterization of a novel P2Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. Blood. 2009;113(17):4110-4113.
50. Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4(4):766-773.
51. Zighetti ML, Carpani G, Sinigaglia E, Cattaneo M. Usefulness of a flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of patients with genetic defects of the platelet P2Y12 receptor for ADP. J Thromb Haemost. 2010;8(10):2332-2334.
52. Cattaneo M, Mannucci PM. Desmopressin. In: Michelson AD, ed. Platelets. San Diego, CA: Academic Press; 2002:855-866.
53. Cattaneo M. ADP receptors antagonists. In: Michelson AD, ed. Platelets. San Diego, CA: Academic Press; 2006:1127-1144.
54. Cattaneo M. New P2Y(12) inhibitors. Circulation. 2010;121(1):171-179.
55. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1(8649):1215-1220. (Pubitemid 19140324)
56. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in highrisk patients: Ticlopidine Aspirin Stroke Study Group. N Engl J Med. 1989;321(8):501-507. (Pubitemid 19203874)
57. Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronaryartery stents. N Engl J Med. 1996;334(17):1084-1089. (Pubitemid 26120185)
58. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998;339(23):1665-1671. (Pubitemid 28550691)
59. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339.
60. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-1717.
61. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331-337.
62. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502. (Pubitemid 32758501)
63. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607-1621.
64. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527-533. (Pubitemid 32772726)
65. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007;154(2):221-231. (Pubitemid 47069129)
66. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108(7):2244-2247. (Pubitemid 44497506)
67. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5(12):2429-2436. (Pubitemid 350154353)
68. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol. 2010;56(2):134-143.
69. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-375.
70. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376(9749):1312-1319.
71. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303(8):754-762.
72. Cuisset T, Frere C, Poyet R, et al. Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. Arch Cardiovasc Dis. 2010;103(1):39-45.
73. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost. 2009;101(2):333-339.
74. Paniccia R, Antonucci E, Maggini N, et al. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost. 2010;104(2):287-292.
75. Kim IS, Jeong YH, Kang MK, et al. Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y(12) assay. J Thromb Thrombolysis. 2010;30(4):486-495.
76. Madsen EH, Saw J, Kristensen SR, Schmidt EB, Pittendreigh C, Maurer-Spurej E. Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention. Clin Chem. 2010;56(5):839-847.
77. Aleil B, Léon C, Cazenave JP, Gachet C. CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring. J Thromb Haemost. 2009;7(10):1747-1749.
78. Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol. 2010;55(22):2427-2434.
79. Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol. 2009;103(1):5-10.
80. Pena A, Collet JP, Hulot JS, et al. Can we override clopidogrel resistance? Circulation. 2009;119(21):2854-2857.
81. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919-933.
82. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015. (Pubitemid 350106708)
83. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29(1):21-30.
84. Sugidachi A, Ogawa T, Kurihara A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost. 2007;5(7):1545-1551. (Pubitemid 46965386)
85. van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost. 2005;31(2):195-204. (Pubitemid 40605194)
86. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 2010;66(5):487-496.
87. van Giezen JJ, Nilsson L, Berntsson P, et al. Ticagrelor binds to the human P2Y receptor independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7(9):1556-1565.
88. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27(9):1038-1047.
89. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. JAm Coll Cardiol. 2007;50(19):1844-1851. (Pubitemid 350007959)
90. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120(25):2577-2585.
91. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057.
92. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361(24):2330-2341.
93. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361(24):2318-2329.
94. Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55(23):2556-2566.
95. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8):774-782. (Pubitemid 44268228)
96. Pocock SJ, Mehran R, Clayton TC, et al. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation. 2010;121(1):43-51.
97. van Hattum ES, Algra A, Lawson JA, Eikelboom BC, Moll FL, Tangelder MJ. Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation. 2009;120(16):1569-1576.